| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11018642 | Digestive and Liver Disease | 2018 | 45 Pages |
Abstract
Application of the Toll-like-receptor 9 (TLR-9) agonist cobitolimod is able to induce remission as assessed by PRO measures in UC patients with moderate-to-severe activity as well as in anti-TNFα experienced and naïve patients supporting the overall efficacy of the substance.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Raja Atreya, Walter Reinisch, Laurent Peyrin-Biroulet, Franco Scaldaferri, Charlotte Admyre, Thomas Knittel, Jan Kowalski, Markus Friedrich Neurath, Christopher Hawkey,